Louise M Kelly

Summary

Publications

  1. ncbi request reprint Genetics of myeloid leukemias
    Louise M Kelly
    Howard Hughes Medical Institute, Brigham and Women s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Annu Rev Genomics Hum Genet 3:179-98. 2002
  2. ncbi request reprint Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
    Ellen Weisberg
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 1:433-43. 2002
  3. ncbi request reprint CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
    Louise M Kelly
    Division of Hematology Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Cell 1:421-32. 2002
  4. pmc PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
    Louise M Kelly
    Division of Hematology Oncology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:8283-8. 2002
  5. ncbi request reprint FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
    Louise M Kelly
    Division of Hematology Oncology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 99:310-8. 2002

Detail Information

Publications5

  1. ncbi request reprint Genetics of myeloid leukemias
    Louise M Kelly
    Howard Hughes Medical Institute, Brigham and Women s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Annu Rev Genomics Hum Genet 3:179-98. 2002
    ..The data supporting this hypothesis and the clinical and therapeutic implications of these observations are reviewed...
  2. ncbi request reprint Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
    Ellen Weisberg
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 1:433-43. 2002
    ..PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors...
  3. ncbi request reprint CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
    Louise M Kelly
    Division of Hematology Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Cell 1:421-32. 2002
    ..Therapeutic efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of FLT3-ITD-induced disease...
  4. pmc PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
    Louise M Kelly
    Division of Hematology Oncology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:8283-8. 2002
    ..The leukemia is transplantable to secondary recipients and is ATRA responsive. These observations document cooperation between PML/RARalpha and FLT3-ITD in development of the murine APL phenotype...
  5. ncbi request reprint FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
    Louise M Kelly
    Division of Hematology Oncology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 99:310-8. 2002
    ..This model system should be useful to assess the contribution of additional cooperating mutations and to evaluate specific FLT3 inhibitors in vivo...